Key Developments: Edwards Lifesciences Corp (EW)

EW on New York Consolidated

87.89USD
9 Jul 2014
Price Change (% chg)

$0.95 (+1.09%)
Prev Close
$86.94
Open
$87.11
Day's High
$87.92
Day's Low
$86.96
Volume
365,014
Avg. Vol
1,158,671
52-wk High
$88.20
52-wk Low
$60.62

Search Stocks

Latest Key Developments (Source: Significant Developments)

Edwards receives FDA clearance for advanced noninvasive monitoring system
Monday, 30 Jun 2014 09:15am EDT 

Edwards Lifesciences Corp:Receives U.S. Food and Drug Administration (FDA) clearance for the ClearSight system.ClearSight system is a noninvasive monitor that provides clinicians access to valuable blood volume and blood flow information for patients at moderate or high risk of post-surgical complications.  Full Article

Medtronic settles global patent litigation with Edwards Lifesciences
Tuesday, 20 May 2014 07:15am EDT 

Edwards Lifesciences Corp:Reached an agreement with Medtronic to settle all outstanding patent litigation between companies, including cases related to transcatheter heart valves.Agreement will result in dismissal of all pending cases or appeals in courts and patent offices worldwide, and includes provision that parties will not litigate patent disputes with each other in field of transcatheter valves for eight-year duration of agreement.Under terms of patent cross-license agreement that is part of settlement, Medtronic will make one-time payment to Edwards of $750 mln.Additionally, Medtronic will pay Edwards quarterly license royalty payments through April 2022.Payments will be based on pct of Medtronic CoreValve sales, subject to a minimum annual payment of $40 mln.Edwards will contribute $50 mln from settlement to Edwards Lifesciences Foundation to support efforts to improve patient care, raise disease awareness and educate clinicians, such as through its Every Heartbeat Matters philanthropic program.  Full Article

Edwards Lifesciences reaffirms FY 2014 guidance; gives Q2 2014 guidance in line with analysts' estimates
Thursday, 24 Apr 2014 04:03pm EDT 

Edwards Lifesciences Corp:Maintains FY 2014 guidance.Continues to expect FY 2014 total sales of $2.05 billion to $2.25 billion.Says excluding special items, the company expects FY 2014 diluted earnings per share to be in a range around $3.10, which includes an assumed $0.10 benefit from change in the treatment of IP litigation expenses.Projects Q2 2014 total sales to be between $525 million and $565 million.Projects Q2 2014 diluted earnings per share, excluding special items, to be between $0.71 and $0.81.FY 2014 revenue of $2.16 billion and EPS of $3.06 - Thomson Reuters I/B/E/S.Q2 2014 revenue of $543 million and EPS of $0.72 - Thomson Reuters I/B/E/S.  Full Article

Edwards Lifesciences Edwards Intuity Elite Valve System receives CE Mark
Friday, 4 Apr 2014 03:00am EDT 

Edwards Lifesciences Corp:Receives CE Mark for the advanced EDWARDS INTUITY Elite valve system.Says it facilitates smaller incisions in surgical aortic valve replacement (AVR) procedures, and is built upon evidence supporting the durability of the Carpentier-Edwards PERIMOUNT heart valve design.  Full Article

Edwards Lifesciences Corp receives CE Mark in Europe for valve-in-valve procedures using the SAPIEN XT transcatheter heart valve
Wednesday, 5 Feb 2014 09:25am EST 

Edwards Lifesciences Corp:Says it has received CE Mark in Europe for valve-in-valve procedures using the SAPIEN XT transcatheter heart valve, providing a minimally invasive treatment option for patients whose surgical mitral or aortic valves require replacement, and who are at extreme risk for surgery.  Full Article

Edwards Lifesciences Corp reaffirms FY 2014 guidance; gives Q1 2014 guidance in line with analysts' estimates
Monday, 3 Feb 2014 04:00pm EST 

Edwards Lifesciences Corp:Says that it continue to expect fiscal 2014 total sales of $2.05 billion to $2.25 billion.Says excluding special items, the company continue to expect diluted earnings per share (EPS )to be a wide range around $3.00.Says for the first quarter of 2014, it project total sales, excluding the impact of the THV reserve, of $500 million to $550 million.Sees first quarter 2014 diluted earnings per share, excluding the renewal of the research and development tax credit and other special items, to be between $0.61 and $0.71.Fiscal 2014 revenue of $2.16 billion and EPS of $3.07 - Thomson Reuters I/B/E/S.First quarter of 2014 revenue of $526 million and EPS of $0.71 - Thomson Reuters I/B/E/S.  Full Article

Edwards Lifesciences Corp gives FY 2014 guidance; EPS guidance in line with analysts' estimates - Conference Call
Monday, 13 Jan 2014 07:00pm EST 

Edwards Lifesciences Corp:Says FY 2014 sales growth could be 1 pct to 10 pct.Says FY 2014 EPS could be $3.FY 2014 revenue of $2.162 billion and EPS of $3 - Thomson Reuters I/B/E/S Estimates.  Full Article

Edwards Lifesciences Corp reaffirms FY 2013 guidance-Conference Call
Monday, 9 Dec 2013 08:00am EST 

Edwards Lifesciences Corp:Reaffirms FY 2013 total sales and earnings guidance, which includes diluted earnings per share of $3.00 to $3.10, excluding special items.FY 2013 revenue of $2.04 bln, EPS of $3.05 - Thomson Reuters I/B/E/S Estimates.  Full Article

Edwards Lifesciences Corp announces appointment of CFO
Thursday, 5 Dec 2013 09:15am EST 

Edwards Lifesciences Corp:Says it has chosen Scott B. Ullem as the company's next Corporate Vice President, Chief Financial Officer (CFO).Says Ullem will succeed Thomas M. Abate, who announced in May his planned retirement.  Full Article

Wohl & Fruchter Files Class Action Lawsuit Against Edwards Lifesciences Corp. And Other Defendants
Friday, 15 Nov 2013 12:45pm EST 

Wohl & Fruchter LLP announced that it has filed a class action lawsuit against Edwards Lifesciences Corp. (Edwards Lifesciences) and certain of its officers. The class action, filed on October 24, 2013, in the United States District Court, Central District of California, and docketed under SACV13-1666-BRO-DFMx, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Edwards Lifesciences between April 25, 2012 and April 23, 2013, both dates inclusive (the "Class Period"). This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.  Full Article

Edwards wins U.S. nod for next generation Sapien XT heart valve system

- Edwards Lifesciences Corp said on Monday that U.S. health regulators approved its next generation heart valve replacement system for high risk patients and those deemed too frail to endure open heart surgery.

Search Stocks